Clinical trials
Hepatocellular Carcinoma clinical trials
Below are recruiting hepatocellular carcinoma clinical trials, each written for real people, not researchers. We’re tracking 589 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05263830Recruiting
Testing Glypican-3 to predict outcomes in liver cancer immunotherapy
This study looks at a blood/tissue marker called Glypican-3 to see who is more likely to do well when treated with immunotherapy for liver cancer. It may help doctors predict outcomes and tailor future care.
ParisAges 18–90 - NCT06265350Recruiting
Freezing lung tumors plus immunotherapy for liver cancer with lung spread
This study tests a combination of treatments—freezing the lung tumors (cryoablation) plus two drugs (cardonilizumab and bevacizumab)—for people with liver cancer that has spread only to their lungs. It may be an option if your first treatment stopped working but your liver tumors are under control.
Guanzhou, GuangdongAges 18–75 - NCT06559761Recruiting
Imaging to predict liver cancer aggressiveness after surgery
This study looks at whether special scans can help doctors better predict how aggressive a person's liver cancer (hepatocellular carcinoma) will be, especially right after surgery. If you are planning to have surgery to remove the tumor as your first treatment, this trial might be a good fit.
Beijing, Beijing MunicipalityAges 18–80 - NCT06821958Recruiting
Radio wave treatment for advanced liver cancer
This trial tests a new type of treatment using low-energy radio waves (called electromagnetic fields) for people with advanced liver cancer that can't be removed by surgery. The goal is to see if adding this therapy can help your immune system fight the cancer better.
BerlinAges 18 years+ - NCT06852820RecruitingPhase 2
PSMA-targeted radioactive therapy for advanced liver cancer
This trial tests a radioactive treatment called 177Lu-PSMA-617 for advanced liver cancer that has not responded to first-line immunotherapy. You need a PSMA-PET scan first to see if your cancer absorbs the treatment.
Cleveland, OhioAges 18 years+ - NCT07291076RecruitingPhase 1/Phase 2
Study of Pumitamig with Ipilimumab for first-line advanced liver cancer
This trial tests a new drug called pumitamig, either alone or with another drug (ipilimumab), for people with advanced liver cancer that hasn't been treated yet. The goal is to see if these drugs can help shrink or control the cancer.
Duarte, CaliforniaAges 18 years+ - NCT06301399RecruitingPhase 2
Rituximab with prior therapy for advanced liver cancer
This trial tests if adding rituximab to previous cancer treatments can help people with advanced hepatocellular carcinoma (a type of liver cancer) that has stopped responding or caused side effects. It aims to see if this combination is safe and effective.
Tianjin, Tianjin MunicipalityAges 17–79 - NCT06607107RecruitingPhase 2
Combination therapy for liver cancer beyond Milan criteria
This trial tests a combination of chemotherapy (mFOLFOX7) plus two targeted/immunotherapy drugs (camrelizumab and apatinib) for people with liver cancer that has grown beyond standard transplant criteria. It aims to shrink tumors and improve outcomes.
Guangzhou, GuangdongAges 18–75 - NCT06478719RecruitingPhase 1/Phase 2
FB-1603 plus TACE for liver cancer patients
This trial tests a new medicine (FB-1603) given along with standard TACE procedure for people with liver cancer. It aims to see if the combination is safe and works better than TACE alone.
Taipei, TaiwanAges 18–85 - NCT04512833Recruiting
CyberKnife radiation for small liver cancer with cirrhosis
This trial tests CyberKnife stereotactic body radiation therapy—targeted high-precision radiation—for small hepatocellular carcinoma (liver cancer) in people with decompensated cirrhosis. It may help if other liver cancer treatments aren’t possible, but it has strict safety rules about tumor spread and nearby organs.
BeijingAges 30–80 - NCT04912765RecruitingPhase 2
New immune vaccine plus nivolumab for liver cancer
This trial studies whether an individualized “neoantigen” cancer vaccine given to immune cells (dendritic cells) plus nivolumab can improve outcomes in people with liver cancer and/or colorectal cancer that has spread only to the liver. It focuses on tumors that can be removed with curative surgery (with or without local ablation) and on people with good enough liver and overall health.
SingaporeAges 21 years+ - NCT05828446Recruiting
Improving liver cancer screening for people at risk
This study looks at ways to improve screening for liver cancer in adults with long-term liver disease. It may help catch liver cancer earlier, which can make treatment easier.
Lausanne, Canton of VaudAges 18 years+ - NCT07122089RecruitingPhase 2
SIRT plus immunotherapy for liver cancer with portal vein clot
This trial tests a two-step approach for liver cancer that has spread into the portal vein. First, you receive internal radiation (SIRT) to shrink the tumor, followed by immunotherapy drugs (durvalumab with or without tremelimumab) to help your immune system fight the cancer. The goal is to see if this combination is safe and effective.
GrenobleAges 18 years+ - NCT07303712Recruiting
Liquid Biopsy for Liver Cancer After Y90 Treatment
This study uses a simple blood test (called a liquid biopsy) to learn more about your liver cancer after you receive a targeted radiation treatment called Y90 radioembolization. The goal is to see if the blood test can help doctors better understand how the cancer responds to treatment.
Palo Alto, CaliforniaAges 18 years+ - NCT07679061Recruiting
Nivolumab plus ipilimumab for liver cancer
This trial tests a combination of two immunotherapy drugs, nivolumab and ipilimumab, as a first treatment for liver cancer that cannot be removed by surgery or has come back after local treatments.
Minato-ku, TokyoAges 18 years+ - NCT06861114Recruiting
Urine test to detect liver cancer return after surgery
This study tests if a simple urine test can help find early signs of liver cancer coming back after surgery. Patients with early-stage liver cancer who have surgery may join to help improve follow-up care.
Guangzhou, GuangdongAges 18–75 - NCT06549829Recruiting
Nutrition coaching before liver cancer surgery
This trial tests whether getting special nutrition support before surgery helps patients with liver cancer recover better and have fewer complications. It may help you feel stronger and heal faster after your operation.
Hangzhou, ZhejiangAges 18–80 - NCT06582017RecruitingPhase 1
Study of QXL138AM for advanced solid tumors and multiple myeloma
This trial tests an investigational drug called QXL138AM for people with advanced solid tumors or multiple myeloma that has not responded to standard treatments. The goal is to see if the drug is safe and effective.
Los Angeles, CaliforniaAges 18 years+ - NCT06788353Recruiting
Liver cancer treatment study for patients not eligible for surgery
This trial is collecting information on how well a treatment (likely TACE, a procedure to block the tumor's blood supply) works for people with liver cancer that cannot be removed by surgery. It aims to see how safe and effective it is for patients who haven't had treatment before or who have a first recurrence.
Guangzhou, GuangdongAges 18–75 - NCT05738616RecruitingPhase 3
Testing lenvatinib plus TACE and immunotherapy before liver surgery
This study tests whether a combination of the drug lenvatinib, a liver treatment called TACE, and the immunotherapy drug camrelizumab can shrink advanced hepatocellular carcinoma enough to make surgery (or “conversion resection”) possible. It may help some people live longer by improving the chance that the cancer can be removed.
Chengdu, SichuanAges 18–75 - NCT06828380RecruitingPhase 2
Immunotherapy with or without radiation for liver cancer
This trial tests whether using immunotherapy alone works as well as immunotherapy combined with radiation for liver cancer that has spread into major blood vessels. The goal is to find the best treatment option for people with this specific type of advanced liver cancer.
GoyangAges 19 years+ - NCT04348838Recruiting
Study of people newly diagnosed with liver cancer in France
This study follows people with hepatocellular carcinoma (HCC), a type of liver cancer, to learn how it changes over time. It may help improve understanding of which patients benefit from different care approaches.
AmiensAges 18 years+ - NCT05620771RecruitingPhase 2
Y-90 radioembolization plus treatment for high-risk liver cancer
This Phase 2 trial tests TheraSphere® (a Y-90 radiation treatment delivered to the liver) combined with standard systemic therapy in people with high-risk hepatocellular carcinoma (HCC). It aims to shrink tumors and improve outcomes for people whose liver cancer is at higher risk to worsen.
Chicago, IllinoisAges 18 years+ - NCT05862337RecruitingPhase 3
New immune plus anti-cancer pills to prevent liver cancer returning
This Phase 3 trial studies anlotinib capsules plus penpulimab (an immune therapy) to help prevent hepatocellular carcinoma from coming back after it has been fully removed or fully destroyed. It may help high-risk patients lower the chance of recurrence and improve survival.
Bengbu, AnhuiAges 18–75
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for hepatocellular carcinoma?
- Yes. Clin2 currently lists 589 recruiting hepatocellular carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a hepatocellular carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a hepatocellular carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.